id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-258117-5gpo8smn	Le Naour, Julie	Trial watch: IDO inhibitors in cancer therapy	2020-06-14		.txt	text/plain	8522	471	34	10, 58, 59 In this setting, preclinical studies have revealed an interesting paradox: while IDO inhibitors have a negligible effect on established tumors as single-agent, combination of IDO inhibitors and immunotherapies including checkpoint blockers targeting cytotoxic T lymphocyte-associated protein 4 (CTLA4) or PD-1 yields a synergistic effect to control cancer burden and favor survival. 142 These disappointing results suggested that this combinatorial therapy did not improve the clinical outcome of melanoma patients receiving pembrolizumab, confirming that the role of epacadostat (or IDO1 inhibitors in general) in advanced solid tumors with robust PD-1 signaling remains unclear. [210] [211] [212] Along similar lines, the Phase III study NCT03661320 compared the efficacy, tolerability and safety of three therapeutic regimens for MIBC: neoadjuvant standard of care chemotherapy with cisplatin [213] [214] [215] [216] [217] and gemcitabine, 218,219 (NAC) versus NAC combined with nivolumab or nivolumab plus BMS-986205, followed by continuation of adjuvant immunotherapy (nivolumab with or without the IDO1 inhibitor) post radical cystectomy.	./cache/cord-258117-5gpo8smn.txt	./txt/cord-258117-5gpo8smn.txt